Open in interactive viewer → charts, metric popovers & call review

SBC Medical Doubles in Twelve Weeks, Then Reports a Quarter That Was Half Arithmetic

A $549M Japanese clinic MSO prints 47% EBITDA margins, promises longevity revenue in 2028, and refuses to buy back stock at 4x EBITDA — a story about operating leverage, inorganic help, and a float being engineered in real time
SBC · Earnings Call · 2026-11-13

On 13 November, SBC Medical Group Holdings — a Japanese operator of 293 mostly self-pay aesthetic and general-medicine clinics, market cap roughly $549 million — reported a third quarter that reads like a different company from the one that filed its last 10-Q. Revenue rose 35% to $59 million. Operating income rose 66% to $26 million. Adjusted EBITDA margin hit 47%, up nine points. And the stock, which had already run +101% in twelve weeks off its August lows, had priced a lot of that in before the print.

The interesting question is not whether the quarter was good. It is which parts of it repeat.

The Inflection Is Real. The Organic Number Is 7%.

Start with the shape of the history, because it explains why 35% growth is possible at all. Through the last filed quarter — the 10-Q covering the period ended 31 July 2026 — revenue was $49 million, up 13% year-on-year but still 22% below the 2024Q3 peak of $56 million, the tail of a two-year decline. Operating margin at 39.8% was climbing back toward a 47.4% peak. So the third quarter did not emerge from a flat line. It emerged from a hole.

And management was candid, in its own way, about the composition. Revenue rose $15.2 million, and the largest piece was not patients: “management services revenue rose 73% year-on-year, reflecting the service fee revisions we announced in August alongside our second quarter results” — Speaker 1, Unknown · 2026-11-13, plus rental revenue on equipment at new clinics and $5.6 million from the newly consolidated Waqoo segment. Strip those out and the underlying clinic engine grew at the rate we already knew: same-clinic revenue up 7% for the nine months, visits up 9%, average spend per visit up 4%.

That is a perfectly good clinic business. It is not a 35% business. And the fee revisions were not a surprise — they were pre-announced in August with explicit arithmetic: “in Q3 and Q4 for this fiscal year, about half of the unrealized gains will be included” — Yuya Yoshida, CFO, COO and AI Evangelist · 2026-08-13. In other words, this quarter's beat was, in a meaningful sense, a scheduled payment. The MSO model converts fee re-rating into margin almost instantly because “our clinics grow, our headcount does not, and the difference is your margin” — Yuya Yoshida, Executive (likely CEO or senior management) · 2026-11-13.

The competitive setup is the genuinely encouraging part, and it too was flagged before it showed up in numbers. In August the CEO argued “at maximum, last year or in the first half of this year, right now, has probably seen the peak of competition” — Yoshiyuki Aikawa, CEO · 2026-08-13. This quarter he got to confirm the shakeout: “quite a few clinics closed their business in light of the intense competition” — Yuya Yoshida, Executive (likely CEO or senior management) · 2026-11-13. Two years of strategic pricing bought share while smaller single-brand operators folded. That is a durable advantage — and it is the thing worth watching in Q4, because the fee revisions will lap.

Longevity, Told for the Third Time

The new material this quarter is a staged roadmap to 2028 built on DNA methylation testing, in-house development of a test to estimate biological age, blood biomarker screening starting November 2026, and eventually AI-generated, doctor-verified protocols — the whole diagnostic-to-intervention loop. The pitch is clever because it attacks from an unusual direction: “Everyone can buy a diagnostic test. Almost no one owns a 293 licensed clinic with physicians and nurses who can act on the result.” — Yuya Yoshida, Executive (likely CEO or senior management) · 2026-11-13 That is the medical infrastructure moat, and it is the only version of a longevity story that a clinic roll-up is actually entitled to tell.

But it is not new, and the honesty matters for anyone extrapolating the +101% move. A year ago the CEO was already describing “the gene screening that is conducted in the United States in order to see the ages of organs can be investigated, for which peptides or hormone endocrinology and supplements, any kinds of therapies can be proposed” — Yoshiyuki Aikawa, CEO · 2026-08-13. The longevity center has been "next year" for at least two calls. What is genuinely new is specificity — named modalities, a dated sequence, a Japan-specific dataset — not the thesis.

And the payoff is distant. “we expect meaningful revenue contribution from around 2028” — Yuya Yoshida, Executive (likely CEO or senior management) · 2026-11-13, which is management's own words, delivered to a stock that doubled in three months on the strength of a fee revision. Between now and then, the clinic network does the work: continued de novo openings at roughly this year's pace, non-aesthetic formats in dentistry, orthopedics and ophthalmology, and M&A in both.

The Cash Problem Nobody Wants to Solve

Here is the tension that makes SBC unusual. The balance sheet is a fortress. Effective net cash stood at $147 million at the last filing, up 3% year-on-year, and management put the current figure above $200 million. Cash generation exceeds accounting profit: free cash flow of $22 million against net income of $11 million, and capital expenditure has fallen 72% year-on-year to $84 thousand. The company funds its own expansion.

An investor on the call did the math out loud: the stock at "only around four times third quarter adjusted EBITDA and nearly 20% free cash flow yield." The answer was no. “we are not considering additional share buyback at this moment” — Yuya Yoshida, Executive (likely CEO or senior management) · 2026-11-13 — cash goes to M&A and de novo clinics first. That is defensible when you can earn high returns on new clinics. It is less defensible when your own founder-controlled float is the reason the multiple is 4x.

Which brings up the real project here, and it is not medical. It is a re-rating campaign. Average daily trading value in October was ~$1 million, 4.1x July. Beneficial shareholders hit 7,300, up 1.6x since July. Through October: 183 one-on-one meetings, 22 conferences. And the most telling detail of the whole call — the presentation itself was AI-narrated, with "please rest assured that the content has been reviewed in advance," and questions submitted by chat rather than asked by live analysts. This is a company marketing itself to a US audience that has barely heard of it, and the independent directors question keeps coming back because “Under our current structure, the CEO holds approximately 80% of the shares” — Yuya Yoshida, Executive (likely CEO or senior management) · 2026-11-13. The selection process is now "concretely" underway — a phrase that has appeared before without a name attached.

One small slip is worth flagging: prepared remarks credit the clinic-OS alliance to AtomicSoftware and its medicalforce platform, while the CFO in Q&A cites a "capital and business alliance with NeuroBrain Dynamics of Taiwan" for the local LLM. Possibly two separate deals, poorly sequenced. Possibly not. In a scripted AI presentation with no live cross-examination, nobody in the room catches it.

What to Watch

Three things. First, Q4 organic same-clinic growth once the August fee revision stops flattering the comparison — that is the only number that proves the operating leverage is structural rather than scheduled. Second, deployment of the cash: an M&A announcement is the bull case; another quarter of it sitting idle at 4x EBITDA is not. Third, a date and a name for independent board appointees.

What changed at SBC this quarter is that a two-year revenue decline definitively ended, a competitor shakeout was confirmed, and a strategy with a 2028 payoff got a calendar. What did not change is that the market is now paying today for revenue management itself dates to 2028 — and a founder owning 80% of the equity decides when, or whether, that bill gets settled.